Discontinue immediately & do not restart treatment if serious allergic/hypersensitivity reactions including SJS & acute anaphylactic reaction/shock occur/develop. Not to start treatment until acute gout attack has completely subsided. Not recommended in patients w/ ischaemic heart disease or CHF; Lesch-Nyhan syndrome; organ transplant recipients. Exacerbation &/or onset of CV disease. Increased TSH values (>5.5 uIU/mL) in patients on long-term treatment. Perform cardiac monitoring in patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of TLS. Flare prophylaxis for at least 6 mth w/ an NSAID or colchicine at treatment initiation is recommended. Patients w/ alteration of thyroid function. Monitor closely for symptoms of allergic/hypersensitivity reactions. Perform LFT prior to treatment, & periodically thereafter. Not recommended in patients concomitantly treated w/ mercaptopurine/azathioprine. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Severe renal impairment (CrCl <30 mL/min). Severe hepatic impairment (Child Pugh Class C). Not to be used during pregnancy & lactation. Childn <18 yr.
Sign Out
